2011
DOI: 10.1016/j.vaccine.2010.11.011
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
30
0

Year Published

2012
2012
2015
2015

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 51 publications
(30 citation statements)
references
References 54 publications
0
30
0
Order By: Relevance
“…[1][2][3] In addition, several plasmid-based gene therapies are currently in clinical trials, and plasmids encoding multiple small interfering RNAs (siRNAs) can be used to silence different genes. [2][3][4][5][6][7][8] However, the use of pDNA as a therapeutic requires that the quality of the plasmid that is produced in bacteria be quantitatively assessed. Regulatory agencies have strict guidelines for plasmid preparations in terms of genomic DNA content and plasmid integrity that greatly exceed standards used in a typical molecular biology laboratory.…”
Section: Introductionmentioning
confidence: 99%
“…[1][2][3] In addition, several plasmid-based gene therapies are currently in clinical trials, and plasmids encoding multiple small interfering RNAs (siRNAs) can be used to silence different genes. [2][3][4][5][6][7][8] However, the use of pDNA as a therapeutic requires that the quality of the plasmid that is produced in bacteria be quantitatively assessed. Regulatory agencies have strict guidelines for plasmid preparations in terms of genomic DNA content and plasmid integrity that greatly exceed standards used in a typical molecular biology laboratory.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, PCR based quantitation of residual plasmid indicated that the potential for integration events into the host genome was low. These data suggested the clinical development of ADVAX delivered by EP in humans [23].…”
Section: Dna Vaccine Deliverymentioning
confidence: 78%
“…In a study involving healthy volunteers, the addition of in vivo EP/ET improved the response rates from zero percent to 88 % at the same 4.0 mg DNA dose [20]. Thus, there is today little doubt that in vivo EP/ET has beneficial effects on DNA transfection, expression, adjuvant effects, and in the end on the primed immune responses.…”
Section: In Vivo Ep/et For Dna Vaccines In Humansmentioning
confidence: 99%